Business
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitorClinical readouts expected in the second half of 2026 across all three programsCash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT),
About this update from Bridgebio Oncology Therapeutics, Inc.
[{"type":"image","alt":"TheRas, Inc. (d/b/a BBOT)","displaySize":"","headline":null,"caption":"TheRas, Inc. (d/b/a BBOT)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/9479f198b092ba1412cb0ee76f46ca4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fHlO5lqk7Y3zBP.mSEEEmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9479f198b092ba1412cb0ee76f46ca4a","width":300,"height":143},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fHlO5lqk7Y3zBP.mSEEEmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9479f198b092ba1412cb0ee76f46ca4a","width":300,"height":143}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical readouts expected in the second half of 2026 across all three programs","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash runway expected to fund operations into 2028","length":49,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":374,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.","length":356,"tagName":"p"},{"type":"text","content":"BBOT's portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition of KRAS in both its ON and OFF states, pan-KRAS coverage across major KRAS mutations, and disruption of RAS-driven PI3Kα activation. Together, these assets uniquely position BBOT to achieve safe, concurrent, high-level suppression of both the MAPK and PI3Kα pathways through a wholly owned internal combination strategy.","length":423,"tagName":"p"},{"typ...